{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:34:29Z","timestamp":1777055669194,"version":"3.51.4"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KU36301-1"],"award-info":[{"award-number":["KU36301-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Pancreatic cancer is the third leading cause of cancer-related death, with a 5-year survival rate of only 10%. Preclinical studies remain essential for identifying novel therapeutic strategies, discovering biomarkers, and deepening the understanding of disease biology. The most frequent driver mutation in pancreatic cancer is the G12D mutation in the KRAS gene, present in approximately 90% of the tumors. A recent study demonstrated complete regression of KRAS-driven pancreatic cancer upon systemic ablation up- and downstream signaling proteins EGFR and C-RAF. Building on these findings, we investigated the therapeutic benefit of combining the EGFR inhibitor erlotinib with the novel pan-RAF inhibitor LXH-254. The anticancer effects of this combination were assessed\n                    <jats:italic>in vitro<\/jats:italic>\n                    in murine and human pancreatic cancer cell lines by evaluating cell proliferation, cell death and phosphorylation of key signaling proteins. Subsequent\n                    <jats:italic>in vivo<\/jats:italic>\n                    studies were performed in an orthotopic murine pancreatic cancer model and in genetically engineered KPC mice, using daily oral administration of LXH-254 (35 mg\/kg) and erlotinib (75 mg\/kg). While the treatment robustly inhibited MAPK signaling and caused significant anti-proliferative effects\n                    <jats:italic>in vitro,<\/jats:italic>\n                    it did not improve survival or reduce tumor burden in either\n                    <jats:italic>in vivo<\/jats:italic>\n                    model. hese results contrast with previous reports of efficacy from monotherapies in xenograft models, highlighting the limitations of current preclinical approaches. Our findings underscore the need to develop more effective pathway-targeted inhibitors, and preclinical models that predict clinical outcomes more accurately.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0347843","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:35:27Z","timestamp":1777052127000},"page":"e0347843","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting pancreatic cancer with combined inhibition of EGFR and RAF"],"prefix":"10.1371","volume":"21","author":[{"given":"Jakob","family":"Brandstetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-3662","authenticated-orcid":true,"given":"Rupert","family":"Palme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3132","authenticated-orcid":true,"given":"Tobias","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Joksch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Vollmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-6294","authenticated-orcid":true,"given":"Simone","family":"Kumstel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"8","key":"pone.0347843.ref001","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"CJ Halbrook","year":"2023","journal-title":"Cell"},{"issue":"5","key":"pone.0347843.ref002","first-page":"375","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"AJ Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"pone.0347843.ref003","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"RL Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"pone.0347843.ref004","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"L Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"pone.0347843.ref005","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"MJ Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0347843.ref006","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.3390\/curroncol30110694","article-title":"A simple overview of pancreatic cancer treatment for clinical oncologists","volume":"30","author":"I Garajov\u00e1","year":"2023","journal-title":"Curr Oncol"},{"key":"pone.0347843.ref007","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1471-2407-14-441","article-title":"FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study","volume":"14","author":"A Zaanan","year":"2014","journal-title":"BMC Cancer"},{"issue":"18","key":"pone.0347843.ref008","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/ijms20184504","article-title":"Chemoresistance in pancreatic cancer","volume":"20","author":"S Zeng","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0347843.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha Signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"SK Shukla","year":"2017","journal-title":"Cancer Cell"},{"issue":"5897","key":"pone.0347843.ref010","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"S Jones","year":"2008","journal-title":"Science"},{"key":"pone.0347843.ref011","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","volume":"155","author":"F Puleo","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0347843.ref012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"EA Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"7592","key":"pone.0347843.ref013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"P Bailey","year":"2016","journal-title":"Nature"},{"key":"pone.0347843.ref014","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: The devil is in the detail","volume":"3","author":"KM Haigis","year":"2017","journal-title":"Trends Cancer"},{"issue":"15","key":"pone.0347843.ref015","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"DS Hong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"pone.0347843.ref016","volume-title":"Erlotinib","author":"J Carter","year":"2025"},{"issue":"6","key":"pone.0347843.ref017","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"R Yaeger","year":"2024","journal-title":"Cancer Discov"},{"issue":"5","key":"pone.0347843.ref018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial","volume":"17","author":"K Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0347843.ref019","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1186\/s12885-025-14388-2","article-title":"Quality of life in patients with metastatic colorectal cancer receiving cytotoxic and cytotoxic plus targeted therapy","volume":"25","author":"HT Pham","year":"2025","journal-title":"BMC Cancer"},{"issue":"4","key":"pone.0347843.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.03.002","article-title":"Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF","volume":"35","author":"MT Blasco","year":"2019","journal-title":"Cancer Cell"},{"key":"pone.0347843.ref021","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00161","article-title":"Design and discovery of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a selective, efficacious, and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic","volume":"63","author":"S Ramurthy","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"pone.0347843.ref022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"H Lavoie","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"pone.0347843.ref023","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Y-J Guo","year":"2020","journal-title":"Exp Ther Med"},{"issue":"10","key":"pone.0347843.ref024","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1021\/acs.molpharmaceut.4c00649","article-title":"Preclinical Evaluation of a Radiolabeled Pan-RAF Inhibitor for RAF-Specific PET\/CT Imaging","volume":"21","author":"W Zhang","year":"2024","journal-title":"Mol Pharm"},{"key":"pone.0347843.ref025","doi-asserted-by":"crossref","first-page":"113458","DOI":"10.1016\/j.ejca.2023.113458","article-title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","volume":"196","author":"F Janku","year":"2024","journal-title":"Eur J Cancer"},{"issue":"7","key":"pone.0347843.ref026","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors","volume":"27","author":"K-A Monaco","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0347843.ref027","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/1753-0407.12624","article-title":"How does CKD affect HbA1c?","volume":"10","author":"Z Bloomgarden","year":"2018","journal-title":"J Diabetes"},{"issue":"35","key":"pone.0347843.ref028","doi-asserted-by":"crossref","first-page":"56395","DOI":"10.18632\/oncotarget.10892","article-title":"Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin","volume":"7","author":"D Zechner","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"pone.0347843.ref029","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10585-011-9398-4","article-title":"Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292","volume":"28","author":"K Furugaki","year":"2011","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"pone.0347843.ref030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3892\/or.2011.1614","article-title":"Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts","volume":"27","author":"T Iwai","year":"2012","journal-title":"Oncol Rep"},{"issue":"7","key":"pone.0347843.ref031","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/biomedicines12071494","article-title":"Evidence-based severity assessment of animal models for pancreatic cancer","volume":"12","author":"T Schreiber","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"pone.0347843.ref032","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/ani15091241","article-title":"Burrowing behavior as robust parameter for early humane endpoint determination in murine models for pancreatic cancer","volume":"15","author":"J Brandstetter","year":"2025","journal-title":"Animals (Basel)"},{"issue":"1","key":"pone.0347843.ref033","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nprot.2006.19","article-title":"Burrowing in rodents: A sensitive method for detecting behavioral dysfunction","volume":"1","author":"RMJ Deacon","year":"2006","journal-title":"Nat Protoc"},{"issue":"59","key":"pone.0347843.ref034","doi-asserted-by":"crossref","DOI":"10.3791\/2607","article-title":"Assessing burrowing, nest construction, and hoarding in mice","author":"R Deacon","year":"2012","journal-title":"J Vis Exp"},{"issue":"3","key":"pone.0347843.ref035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","article-title":"Assessing nest building in mice","volume":"1","author":"RMJ Deacon","year":"2006","journal-title":"Nat Protoc"},{"issue":"6","key":"pone.0347843.ref036","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nmeth.1455","article-title":"Coding of facial expressions of pain in the laboratory mouse","volume":"7","author":"DJ Langford","year":"2010","journal-title":"Nat Methods"},{"issue":"3","key":"pone.0347843.ref037","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0016-6480(02)00620-2","article-title":"Effects of sex and time of day on metabolism and excretion of corticosterone in urine and feces of mice","volume":"130","author":"C Touma","year":"2003","journal-title":"Gen Comp Endocrinol"},{"issue":"4","key":"pone.0347843.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266601","article-title":"Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism","volume":"17","author":"S Kumstel","year":"2022","journal-title":"PLoS One"},{"issue":"43","key":"pone.0347843.ref039","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.3748\/wjg.v18.i43.6226","article-title":"Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach","volume":"18","author":"F Lange","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"15","key":"pone.0347843.ref040","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-13-3377","article-title":"Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma","volume":"20","author":"MH Wong","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"pone.0347843.ref041","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/0008-5472.CAN-12-1453","article-title":"Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals","volume":"73","author":"K Miyabayashi","year":"2013","journal-title":"Cancer Res"},{"key":"pone.0347843.ref042","article-title":"Grading animal distress and side effects of therapies","author":"S Kumstel","year":"2020","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"pone.0347843.ref043","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.taap.2012.01.025","article-title":"A less stressful alternative to oral gavage for pharmacological and toxicological studies in mice","volume":"260","author":"MK Walker","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"pone.0347843.ref044","doi-asserted-by":"crossref","first-page":"14084","DOI":"10.1038\/s41598-019-50682-3","article-title":"A novel multi-parametric analysis of non-invasive methods to assess animal distress during chronic pancreatitis","volume":"9","author":"A Abdelrahman","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0347843.ref045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cam4.1956","article-title":"Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer","volume":"8","author":"YJ Lee","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"pone.0347843.ref046","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/annonc\/mdv546","article-title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","volume":"27","author":"N Joseph","year":"2016","journal-title":"Ann Oncol"},{"key":"pone.0347843.ref047","doi-asserted-by":"crossref","first-page":"104352","DOI":"10.1016\/j.ebiom.2022.104352","article-title":"Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition","volume":"86","author":"X Shi","year":"2022","journal-title":"EBioMedicine"},{"issue":"35","key":"pone.0347843.ref048","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3748\/wjg.14.5403","article-title":"Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line","volume":"14","author":"Y-Y Lu","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"8","key":"pone.0347843.ref049","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/1759-7714.13487","article-title":"Combination effects of ellagic acid with erlotinib in a Ba\/F3 cell line expressing EGFR H773_V774 insH mutation","volume":"11","author":"C Xie","year":"2020","journal-title":"Thorac Cancer"},{"issue":"2","key":"pone.0347843.ref050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1245\/s10434-013-3329-3","article-title":"Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10","volume":"21","author":"K Yamamura","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"pone.0347843.ref051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/apc.2020.03.03","article-title":"Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma","volume":"3","author":"M He","year":"2020","journal-title":"Ann Pancreat Cancer"},{"issue":"7","key":"pone.0347843.ref052","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1158\/0008-5472.CAN-05-3827","article-title":"Genetically engineered models have advantages over xenografts for preclinical studies","volume":"66","author":"OJ Becher","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0347843.ref053","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"ME Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"pone.0347843.ref054","doi-asserted-by":"crossref","first-page":"114710","DOI":"10.1016\/j.celrep.2024.114710","article-title":"Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells","volume":"43","author":"T Sevrin","year":"2024","journal-title":"Cell Rep"},{"key":"pone.0347843.ref055","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"D Westover","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"pone.0347843.ref056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccr.2012.01.017","article-title":"The RAF inhibitor paradox revisited","volume":"21","author":"AD Cox","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"pone.0347843.ref057","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Z Yao","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"pone.0347843.ref058","doi-asserted-by":"crossref","first-page":"104634","DOI":"10.1016\/j.jbc.2023.104634","article-title":"Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib","volume":"299","author":"E Tkacik","year":"2023","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0347843.ref059","first-page":"665","article-title":"Drug resistance in targeted cancer therapies with RAF inhibitors","volume":"4","author":"U Degirmenci","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"pone.0347843.ref060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccell.2021.01.008","article-title":"RAF1 kinase activity is dispensable for KRAS\/p53 mutant lung tumor progression","volume":"39","author":"M Sanclemente","year":"2021","journal-title":"Cancer Cell"},{"issue":"14","key":"pone.0347843.ref061","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1073\/pnas.141224398","article-title":"Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism","volume":"98","author":"J Chen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5705","key":"pone.0347843.ref062","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1126\/science.1103233","article-title":"Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1","volume":"306","author":"E O\u2019Neill","year":"2004","journal-title":"Science"},{"issue":"7404","key":"pone.0347843.ref063","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"S Misale","year":"2012","journal-title":"Nature"},{"issue":"3","key":"pone.0347843.ref064","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ccr.2013.01.023","article-title":"Selective requirement of PI3K\/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer","volume":"23","author":"S Eser","year":"2013","journal-title":"Cancer Cell"},{"issue":"6490","key":"pone.0347843.ref065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/370527a0","article-title":"Phosphatidylinositol-3-OH kinase as a direct target of Ras","volume":"370","author":"P Rodriguez-Viciana","year":"1994","journal-title":"Nature"},{"issue":"2","key":"pone.0347843.ref066","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","article-title":"Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition","volume":"69","author":"OK Mirzoeva","year":"2009","journal-title":"Cancer Res"},{"issue":"39","key":"pone.0347843.ref067","doi-asserted-by":"crossref","first-page":"24415","DOI":"10.1073\/pnas.2002520117","article-title":"Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS\/P53 mutant lung adenocarcinomas","volume":"117","author":"L Esteban-Burgos","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0347843.ref068","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1017\/ice.2017.234","article-title":"Risk factors for Staphylococcus aureus acquisition in the neonatal intensive care unit: A matched case-case-control study","volume":"39","author":"MC Washam","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"pone.0347843.ref069","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin \u03b21\/FAK signaling","volume":"27","author":"E Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"pone.0347843.ref070","article-title":"Avutometinib and defactinib: First approval","author":"HA Blair","year":"2025","journal-title":"Drugs"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:35:36Z","timestamp":1777052136000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347843"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Sowa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347843","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}